

IFW



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket: FISHMAN 19A

In re Application of:	)	Conf. No.: 7305
	)	
Pnina FISHMAN et al.	)	Art Unit:
	)	
Appln. No.: 10/565,161	)	Examiner: Not Yet Known
	)	
Filed: November 30, 2005	)	Washington, D.C.
	)	
For: TREATMENT OF INFLAMMATION	)	April 23, 2007

INFORMATION DISCLOSURE STATEMENT [IDS]

Honorable Commissioner for Patents  
U.S. Patent and Trademark Office  
Customer Service Window  
Randolph Building, Mail Stop Amendment  
401 Dulany Street  
Alexandria, VA 22314

Sir :

This Information Disclosure Statement is submitted in accordance with 37 CFR §§1.97, 1.98, and it is requested that the information set forth in this statement and in the listed documents be considered during the pendency of the above-identified application, and any other application relying on the filing date of the above-identified application or cross-referencing it as a related application.

1. This IDS should be considered, in accordance with 37 CFR §1.97, as it is filed before the mailing date of a first office action on the merits.

2. In accordance with 37 CFR §1.98, this IDS includes a list (e.g., form PTO/SB/08A) of all patents, publications, or other information submitted for consideration by the office, either incorporated into this IDS or as an attachment hereto. A copy of each document listed is attached, except as explained below:

[X] A. Documents AA-AE are U.S. patent(s) and/or published application(s). 37 CFR §1.98(a)(2)(ii) does not require the filing of legible copies of U.S. patents or U.S. patent application publications unless required by the Office.

3. Document AR is not in the English language. In accordance with §1.98(a)(3), Applicant(s) states that a concise explanation of the relevance of document AR is found in the attached International Search Report and Written Opinion dated March 23, 2006 (see reply to Comment 68 in the preamble to the final rules; 1135 OG 13 at 20).


4. No explanation of relevance is necessary for documents in the English language (see reply to Comments 67 and 68 in the preamble to the final rules; 1135 OG 13 at 20).

5. In accordance with 37 CFR §§1.97(g) and (h), the filing of this IDS should not be construed as a representation that a search has been made or that information cited is, or is considered to be, material to patentability as defined in §1.56 (b), or that any cited document listed or attached is (or constitutes) prior art. Unless otherwise indicated, the date of publication indicated for an item is taken from the face of the item and Applicant(s) reserves the right to prove that the date of publication is in fact different.

Respectfully submitted,


BROWDY AND NEIMARK  
Attorneys for Applicant(s)

By:

  
Sheridan Neimark  
Reg. No. 20,520

624 Ninth Street, N.W., Suite 300  
Washington, D.C. 20001-5303  
Telephone: (202) 628-5197  
Facsimile: (202) 737-3528  
SN:ma

G:\bn\c\cohn\fishman19A\pto\2007-04-23 IDS Form.doc



Substitute form 1449, 1-10

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1

of 3

**Complete if Known**

Application Number	10/565,161
Filing Date	November 30, 2005
First Named Inventor	Pnina FISHMAN
Confirmation No.	7305
Examiner Name	Not Yet Known
Attorney Docket Number	FISHMAN=19A

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	AA	US-2004/ 0167094 A1	08-26-2004	FISHMAN et al.	
	AB	US-2004/0137477 A1	07-15-2004	FISHMAN et al.	
	AC	US-2005/0074451	04-07-2005	YEDNOCK et al.	
	AD	US-2005/0065192	03-24-2005	YEDNOCK et al.	
	AE	US-2002/0119924	08-29-2002	BENDELE et al.	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				
	AF	AU 200051825 A1	10-26-2000	FELDMANN et al.		

Examiner  
SignatureDate  
Considered

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2

of 3

**Complete if Known**

Application Number	10/565,161
Filing Date	November 30, 2005
First Named Inventor	Prina FISHMAN
Group Art Unit	7305
Examiner Name	Not Yet Known
Attorney Docket Number	FISHMAN=19A

**NON PATENT LITERATURE DOCUMENTS / OTHER INFORMATION**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS); title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	AG	FISHMAN et al., <i>Evidence for Involvement of Wnt Signaling Pathway in IB-MECA Mediated Suppression of Melanoma Cells</i> ; <u>Oncogene</u> , Vol. 21, pp.4060-4064 (2002)	
	AH	FISHMAN et al., <i>Targeting the A3 Adenosine Receptor for Cancer Therapy: Inhibition of Prostate Carcinoma Cell Growth by A3AR Agonist</i> ; <u>Anticancer Research</u> Vol. 23: pp. 2077-2083 (2003)	
	AI	MADI et al., <i>A3 Adenosine Receptor Activation in Melanoma Cells, Association Between Receptor Fate and Tumor Growth Inhibition</i> ; <u>The Journal of Biological Chemistry</u> , Vol. 278, No. 43, pp.42121-42130, October 24, 2003	
	AJ	OHANA et al., <i>Inhibition of Primary Colon Carcinoma Growth and Liver Metastasis by the A3 Adenosine Receptor Agonist CF101</i> ; <u>British Journal of Cancer</u> , Vol. 89, pp. 1552-1558 (2003) XP-002332046	
	AK	FISHMAN et al., <i>An Agonist to the A3 Adenosine Receptor Inhibits Colon Carcinoma Growth in Mice Via Modulation of GSK-3<math>\beta</math> and NF-<math>\kappa</math>B</i> ; <u>Oncogene</u> Vol. 23, pp.2465-2471 (2004)	
	AL	SZABO et al., <i>Suppression of Macrophage Inflammatory Protein (MIP)-1<math>\alpha</math> Production and Collagen-Induced Arthritis by Adenosine Receptor Agonists</i> ; <u>British Journal of Pharmacology</u> , Vol. 125, pp. 379-387 (1998)	
	AM	MABLEY et al., <i>The Adenosine A3 Receptor Agonist, N6-(3-Iodobenzyl)-Adenosine-5'-N-Methyluronamide, is Protective in Two Murine Models of Colitis</i> ; <u>European Journal of Pharmacology</u> , Vol. 466, pp. 323-329, 2003	
	AN	BAHARAV et al., <i>Antiinflammatory Effect of A3 Adenosine Receptor Agonists in Murine Autoimmune Arthritis Models</i> ; <u>Journal of Rheumatology</u> , Vol. 32; No. 3, pp. 469-76, 2005	
	AO	MONTESINTOS et al., <i>Adenosine A2A or A3 Receptors are Required for Inhibition of Inflammation by Methotrexate and Its Analog MX-68</i> ; <u>Arthritis &amp; Rheumatism</u> , Vol. 48, No.1, pp.240-247, January 2003.	
	AP	MADI et al., <i>The A3 Adenosine Receptor Is Highly Expressed in Tumor Versus Normal Cells: Potential Target for Tumor Growth Inhibition</i> ; <u>Clinical Cancer Research</u> , Vol. 10, pp. 4472-4479, July 1, 2004	
	AQ	GESSEI et al., <i>Elevated Expression of A3 Adenosine Receptors in Human Colorectal Cancer is Reflected in Peripheral Blood Cells</i> ; <u>Clinical Cancer Research</u> , Vol.10, 5895-5901, September 1, 2004	
	AR	CHAN et al., <i>Molecular Action of Methotrexate in Inflammatory Diseases</i> ; <u>Arthritis Research</u> , Vol. 4, No. 4; 4, pp. 266-273, 2002.	

Examiner  
SignatureDate  
Considered

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

(use as many sheets as necessary)

Sheet	2
-------	---

of	3
----	---

Attorney Docket Number

FISHMAN=19A

**Complete if Known**

Application Number	10/565,161
--------------------	------------

Filing Date	November 30, 2005
-------------	-------------------

First Named Inventor	Pnina FISHMAN
----------------------	---------------

Group Art Unit	7305
----------------	------

Examiner Name	Not Yet Known
---------------	---------------

Attorney Docket Number	FISHMAN=19A
------------------------	-------------

**NON PATENT LITERATURE DOCUMENTS / OTHER INFORMATION**

Examiner  
Signature

Date \_\_\_\_\_

Considered

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.